InvestorsHub Logo
Followers 57
Posts 5697
Boards Moderated 0
Alias Born 12/13/2004

Re: Titan V post# 1104

Saturday, 10/08/2016 1:17:50 PM

Saturday, October 08, 2016 1:17:50 PM

Post# of 6034
Those are very interesting results for both Merck and Roche's drug. In both cases they had 76% non-responders which included 5% who dropped out due to side effects! The big question is how would HS-110 COMBINE with these drugs? As a monotherapy HS-110 would be safer...and might be just as effective...but the combination could be outstanding. Merck and Roche should both be interested!

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News